Average Insider

Where insiders trade, we follow

$NGNE
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Healthcare
Sector
Biotechnology
Industry
Rachel L. McMinn
CEO
107
Employees
$36.80
Current Price
$309.94M
Market Cap
52W Low$15.93
Current$36.8097.8% above low, 2.2% below high
52W High$37.27

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys00--All Sells
Sells15$339,961.769,600
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jul 6, 2026
Cvijic Christine Mikail
Director
Sale600$36.02$21,612.60View Details
Jul 7, 2026
Cvijic Christine Mikail
Director
Sale4,200$36.13$151,762.80View Details
Jul 2, 2026
Cvijic Christine Mikail
Director
Sale2,531$34.58$87,519.45View Details
Jul 2, 2026
Cvijic Christine Mikail
Director
Sale1,530$35.23$53,897.31View Details
Jul 1, 2026
Cvijic Christine Mikail
Director
Sale739$34.06$25,169.60View Details
12 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Version: v26.7.3